Kidney transplant recipients on an immunosuppressive regimen of sirolimus plus cyclosporine who had their cyclosporine withdrawn at an early stage had significantly better graft survival than patients who remained on cyclosporine. The advantage appeared to be related to significantly improved kidney function in the patients in whom cyclosporine was withdrawn, reported Graeme Russ, MD, at the American Transplant Congress 2005 in Seattle, Wash.
The finding comes from 4-year data from the Rapamune Maintenance Regimen study, the largest cyclosporine withdrawal study to date. In the study, 430 of 525 enrolled patients were eligible to be randomized to remain on cyclosporine, sirolimus, and steroids or to have the cyclosporine withdrawn at 3 months, remaining on a maintenance regimen of sirolimus and steroids.
At 4 years, the rates of biopsy-proven acute rejection were not significantly different between the 2 groups-15.8% in patients maintained on cyclosporine and 20.5% in patients in whom cyclosporine had been withdrawn (P=.260).
Outcomes were then assessed according to renal function at the time of conversion (3 months). Patients were divided into quartiles based on calculated glomerular filtration rate (GFR): <45 mL/min, 45 to 56 mL/min, >56 to 67 mL/min, and >67 mL/min.
"In all groups, kidney function was better at 4 years with withdrawal of cyclosporine," said Dr Russ, professor and director of nephrology and transplantation services, The Queen Elizabeth Hospital, Woodville, South Australia. "GFR improved and continued to improve over 48 months with cyclosporine withdrawal but stayed the same or dropped with continued cyclosporine," he said.
Overall, mean GFR was 58.3 mL/min in patients who had cyclosporine withdrawn compared with 43.8 mL/min in those maintained on cyclosporine (P<.001).
Mortality increased with declining renal function in either treatment group.
Patients in the quartile with the lowest calculated GFR at baseline derived the most benefit from cyclosporine withdrawal, according to Dr Russ. In this quartile, the difference in graft survival was statistically significant in favor of the sirolimus maintenance regimen compared with the continued cyclosporine regimen. No significant difference in graft survival emerged between the treatment groups in patients with renal function in the highest 3 quartiles.
The side effect profile was similar between treatment groups in all 4 quartiles.
"Early, progressive, and complete withdrawal of cyclosporine from a combination of sirolimus, cyclosporine, and steroids is preferable to continuing on this regimen, irrespective of baseline renal function," said Dr Russ. "The difference was most marked in patients with baseline calculated GFR <45 mL/min."
There is no current consensus on the optimal timing of cyclosporine withdrawal in kidney transplant recipients, said Myron Kauffman, MD, senior research scientist at the United Network for Organ Sharing (UNOS). "In general, the aim is to start withdrawing before damage occurs but we don't know when exactly that is right now," he said. "UNOS databases will provide the numbers to make this determination."
Get the latest industry news, event updates, and more from Managed healthcare Executive.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 31st 2025In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 31st 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 31st 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More